A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 716 participants.

Also called NCT01106651

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 716 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01106651
Other papers using this trial's data
  • Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes Journal of the American College of Cardiology, 2017-08-08 DOI, PubMed 28619659
  • Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial Hospital practice (1995), 2013-04 DOI, PubMed 23680739
  • Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin The Journal of clinical endocrinology and metabolism, 2016-01 DOI, PubMed 26580234, PMC4701848 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Colombia, France, Greece, Hong Kong SAR China, India, New Zealand, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01106651. Randomized; triple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2013-05-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Canagliflozin 100 mg
Intervention (Drug)
Canagliflozin 300 mg
Intervention (Drug)
Antihyperglycemic agent(s)
Intervention (Drug)
Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01106651
Content hash
eee203fc3daf7883d6969f1a7825dcfe5092354cd831b67ed219772401979f3d